在澳大利亚实施DPYD基因定型以预测化疗毒性:可行性研究
Cassandra White1,2, Christine Paul1,2, Esther Liet3
1College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
Internal medicine journal
|April 11, 2025
概括
对于澳大利亚癌症患者来说,DPYD基因定型是可行的,周转时间为7天. 这种精确的瘤学方法可以减少胺的毒性,并提高患者的安全性.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 临床化学 临床化学
背景情况:
- 实施药物基因组指导的癌症治疗在公平有效的大规模应用中提出了挑战.
- DPYD基因型鉴定识别了患有严重甲胺 (FP) 毒性风险的患者,这是澳大利亚常见的化疗方案.
- 尽管国际标准化,目前的澳大利亚实践尚未正式采用DPYD变种查.
研究的目的:
- 确定澳大利亚患者四种关键DPYD变异的基因型化周转时间 (TAT).
- 为了识别DPYD变异载体中的胺毒性.
- 分析医疗保健利益相关者对实施DPYD基因定型的观点,包括障碍和促进因素.
主要方法:
- 实时聚合酶链反应 (PCR) 用于DPYD变种的基因定型.
- 通过半结构化问卷收集有关利益相关者的观点的定性数据.
主要成果:
- 104名患者在24个月内获得了7.2天 (5.2个工作日) 的平均TAT.
- 16名DPYD变种携带者中有9人经历了3-4级毒性,包括ICU入院和1人死亡.
- 实施的主要障碍包括临床环境和资源,而改善患者护理的动机是主要的推动因素.
结论:
- 在接受FP化疗的患者中,DPYD基因定型是提高精确瘤学的可行策略.
- 7天的TAT被利益相关者和国家瘤学团体认为是可以接受的.
- 这项试点研究为澳大利亚国家项目提供了关键数据,评估DPYD基因造型对FP耐受性,患者安全性和成本效益的影响.
相关概念视频
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
208
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
208
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69